PARP inhibitors in prostate cancer : time to narrow patient selection?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Expert review of anticancer therapy - 20(2020), 7 vom: 06. Juli, Seite 523-526 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Markowski, Mark C [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.03.2021 Date Revised 23.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14737140.2020.1781622 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311004636 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311004636 | ||
| 003 | DE-627 | ||
| 005 | 20231225141323.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14737140.2020.1781622 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1036.xml |
| 035 | |a (DE-627)NLM311004636 | ||
| 035 | |a (NLM)32521178 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Markowski, Mark C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PARP inhibitors in prostate cancer |b time to narrow patient selection? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2021 | ||
| 500 | |a Date Revised 23.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a PARP inhibitors | |
| 650 | 4 | |a metastatic castration-resistant prostate cancer | |
| 650 | 4 | |a niraparib | |
| 650 | 4 | |a olaparib | |
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a rucaparib | |
| 650 | 4 | |a talazoparib | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
| 650 | 7 | |a Poly(ADP-ribose) Polymerases |2 NLM | |
| 650 | 7 | |a EC 2.4.2.30 |2 NLM | |
| 700 | 1 | |a Antonarakis, Emmanuel S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of anticancer therapy |d 2001 |g 20(2020), 7 vom: 06. Juli, Seite 523-526 |w (DE-627)NLM11982020X |x 1744-8328 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2020 |g number:7 |g day:06 |g month:07 |g pages:523-526 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14737140.2020.1781622 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2020 |e 7 |b 06 |c 07 |h 523-526 | ||